Comparative Pharmacology
Head-to-head clinical analysis: CYSTEINE HYDROCHLORIDE versus ENBUMYST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSTEINE HYDROCHLORIDE versus ENBUMYST.
CYSTEINE HYDROCHLORIDE vs ENBUMYST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cysteine hydrochloride serves as a precursor to glutathione, an important antioxidant. It also provides a source of cysteine for protein synthesis and acts as a mucolytic agent by reducing disulfide bonds in mucus glycoproteins, thereby decreasing viscosity.
Acetylcysteine reduces mucus viscosity by cleaving disulfide bonds in mucoproteins, facilitating airway clearance. It also restores glutathione levels in acetaminophen toxicity.
Intravenous: 0.8-1 g/m²/day divided every 6 hours for acetaminophen poisoning; for parenteral nutrition, 0.66-1.7 g of cysteine/kg/day (as hydrochloride).
600 mg orally twice daily (total daily dose 1200 mg) for 12 weeks in combination with other anti-TB drugs.
None Documented
None Documented
Terminal elimination half-life: 1.5-3 hours in adults with normal renal function; prolonged in renal impairment (up to 8-10 hours in severe cases).
Terminal half-life: 6-8 hours in healthy adults; prolonged in hepatic impairment (up to 12 hours) and severe renal impairment (up to 10 hours).
Renal: 40-60% as unchanged drug and metabolites; fecal: <5%; minor biliary elimination; route of administration (e.g., intravenous) influences exact percentages.
Renal: 30% unchanged; biliary/fecal: 70% as metabolites.
Category C
Category C
Mucolytic
Mucolytic